FDA Inspection 1042476 — David Dolezil
The FDA completed an inspection of David Dolezil on Feb 7, 2018 in Prague 2, 120 00. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 7, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Prague 2, 120 00 (Czech Republic)
Additional Details
Clinical Investigator (CI)